Stay updated with breaking news from Mabus mania. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arbutus Biopharma (NASDAQ:ABUS – Get Rating) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday. Several other research analysts have also commented on ABUS. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Arbutus […] ....
Federal Circuit emphasized a litany of Patent Act examples that lend themselves to a holding that only human beings can be considered inventors. Federal Circuit closely adhered to the Patent Act’s plain meaning, holding that artificial intelligence cannot be an inventor. ....
High school, more than 5 million students have experienced sexual misconduct, ranging from harassment to assault. cbs s meg oliver explains how the abuse is often overlooked.% reporter: when some schools hear allegations of teacher sexual abuse, they often try to make them go away quietly, without any record. called patching the trash. reporter: passing the trash. and when they move on, would they write them recommendation letters? yeah, they would give them recommendations, they would give them approvals. reporter: on average, one offender passes through three different school districts before they are stopped. we found one teacher was able to abus we focused on one district in redlands, california, where 50 survivors have accused 25 teachers of sexual misconduct from 1999 to 2022. when you were a sophomore, who was your theater teacher? joel koonce. reporter: joel koonce was hired by redlands high school in 2016, after he was fired from a texas summer camp. ....
Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 4,260,000 shares, a decrease of 13.9% from the March 31st total of 4,950,000 shares. Based on an average daily volume of 911,700 shares, the days-to-cover ratio is currently 4.7 days. […] ....
StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Get Rating) from a buy rating to a hold rating in a report published on Tuesday morning. ABUS has been the subject of several other research reports. Chardan Capital reissued a buy rating and set a $6.00 price objective on shares of Arbutus Biopharma in a research […] ....